that causes Lyme disease is transmitted to humans through the bite of infected ticks, and can cause fever, headache, fatigue, and a skin rash. If left untreated, infection can spread to joints, the heart, and the nervous system. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics, but some individuals develop post-treatment Lyme disease syndrome , which can cause long-lasting symptoms like severe joint pain and neurocognitive issues.
"Bacteria are more complex organisms than viruses, and therefore it can be more challenging to develop effective vaccines against them," said senior author, Norbert Pardi, Ph.D., an assistant professor of Microbiology."Here we were able to identify a target for a mRNAThe vaccine, described recently in the journal technology employed in the Pfizer and Moderna SARS-CoV-2 vaccines, which was pioneered at Penn. Along with mRNA vaccine pioneer Drew Weissman, MD, Ph.D.
Tests in animal models showed that the mRNA vaccine targeting OspA induced a strong antigen-specific antibody and T-cell response after a single vaccination that could protect from infection of B. burgdorferi. What's more, the vaccine elicited a strong memory B cell response, which can be activated much later to help prevent infection by B. burgdorferi long after the vaccine is administered.
"Cases of Lyme disease have been rising sharply in the United States, underscoring the need for a vaccine to protect individuals from ," said Pardi."The mRNA technology shows great promise for use in developing a vaccine that may prevent Lyme disease and subsequent development of the debilitating symptoms of PTLDS."Matthew Pine et al, Development of an mRNA-lipid nanoparticle vaccine against Lyme disease,
Education Education Latest News, Education Education Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NECN - 🏆 20. / 71 Read more »